Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (NDUFV2)
- Target
- NDUFV2
- Molecular classification
- Enzyme, Mitochondrial respiratory chain complex I core subunit, Oxidoreductase
01
Overview
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (NDUFV2) is a core nuclear-encoded subunit of mitochondrial respiratory chain complex I, responsible for catalyzing electron transfer from NADH to ubiquinone, a critical step in cellular energy metabolism[1][2][4][6]. The protein contains a conserved iron-sulfur cluster ([2Fe-2S] N1a) and is localized to the inner mitochondrial membrane as part of the complex I peripheral arm[4][6]. NDUFV2 plays an essential role in electron transport and redox reactions. Mutations are linked to several diseases, including neurodegenerative and psychiatric disorders, and mitochondrial cardiomyopathies[1][4][7]. This subunit is indispensable for normal mitochondrial function and ATP production, making it a validated therapeutic target for conditions related to mitochondrial dysfunction[1][7].
- Other names
- NADH:ubiquinone oxidoreductase core subunit V2NADH-ubiquinone oxidoreductase 24 kDa subunitComplex I 24kDa subunitNADH dehydrogenase (ubiquinone) flavoprotein 2, mitochondrialNuclear-encoded mitochondrial NADH-ubiquinone reductase 24Kd subunitMC1DN7EC 7.1.1.2
02
Mechanism of action
Drugs aimed at NDUFV2 or complex I typically inhibit or modulate electron transfer, affecting mitochondrial metabolism and reactive oxygen species production.
03
Biological functions
Electron transfer in mitochondrial respiratory chainMitochondrial electron transport, NADH to ubiquinoneCardiac muscle tissue developmentNervous system developmentRedox/oxidoreductase activity
04
Disease associations
Neurodegenerative disease (Parkinson’s disease, Alzheimer’s disease)Psychiatric disorders (Bipolar disorder, Schizophrenia)Cardiovascular disease (hypertrophic cardiomyopathy)Mitochondrial complex I deficiencyProgressive cavitating leukoencephalopathyEncephalopathy
05
Safety considerations
Potential for mitochondrial toxicity/respiratory chain inhibition when modulating complex IRisk of exacerbating energetic failure or ROS production
06
Interacting drugs
NADH (nutraceutical; not a direct inhibitor or activator—no well-characterized approved drugs specifically target NDUFV2 as a molecular target[6])
07
Biomarkers
Genetic mutations in NDUFV2 (used for diagnosis and prognosis of certain mitochondrial disorders)Expression levels in mitochondrial diseases
Beyond the preview
Go deeper on NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (NDUFV2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (NDUFV2).